Erfahrung ist dann relevant, wenn sie die aktuelle Entscheidung verbessert.
S&P verbindet medizinische, wissenschaftliche, kommerzielle und unternehmerische Erfahrung aus Pharma, Biotech, MedTech und ausgewählten Digital Health Situationen. Unsere Arbeit reicht von Beratung und Projektführung bis zu operativer Interim Verantwortung.
Unsere Erfahrungsbasis umfasst die nachstehenden zwölf medizinischen und technologischen Fachgebietsgruppen. Die Grafik dokumentiert die in unserer Ausgangspräsentation aufgeführten Bereiche aus Analyse, Beratung und Projektarbeit.
Expertise in Indication & Technology FieldsGrafik in englischer Sprache. Zum Lesen vergrößern; mit dem Zurück-Knopf zur Seite zurückkehren.
Fachgebiete im Detail
Fachliche Details aus der Originalgrafik (Englisch)
DIC / Multiple Organ Failure acc. to Septicemia, Polytrauma, Burns, Cancers,
Re-Occlusion after coronary artery bypass grafting (CABG )
Percutaneous transluminal angioplasty and coronary angioplasty (PTA/PTCA)
Re-Occlusion after thrombolysis in acute myocardial infarction-prevention,
Peripheral arterial Bypass - Prevention of Re-occlusion
Deep Vein Thrombosis of patients with high risks such as Hip Surgery and major abdominal Surgery Pulmonary Embolism
Heparin-induced Thrombocytopenia
Thombosis in Patients undergoing dialysis
Biotechnology
Biopharmaceuticals
Biomarkers
Biosimilars
Genomics
Proteomics
Molecular Biology
Biochemical Processes
Industrial Separations
DNA Profiling For Forensics & Paternity Testing
Woundcare
VAC-Woundhealing
Decubital Ulcers/ Diabetic Ulcers / Ulcera Cruris
Hemorrhoides
Infection / Diseases
Mycotic Diseases
Hepatitis B and C
Bacterial
Viral Diseases
HIV
Flu
Dermatology / Allergology
Psoriasis
Ekcemas
Allergies/Asthma
Cutaneous Infections (mycotic, bacterial)
Diagnostics
Laboratory Testing
Isotopes / Scintigraphy
Plasma-Levels etc.
RAID’s
Ultra-Sound / X-Ray
Tumor Markers
CNS-Diseases
Epilepsy
Depression / Anxiety / Insomnia
Parkinson’s Disease
Schizophrenia
Alzheimers Disease
Multiple Sclerosis
Alcohol Disease
Pulmonary Diseases
COPD (Chron. Obstr. Pulm. Dis.)
RDS (Resp. Distr. Syndr.)
Asthma
Shock Lung
Pulmonary Hypertension
Anesthesiology / Pain / Rheumatoid Diseases
Opioids & Non-Opioids
Patches
Devices / Catheterizations
NSAID‘s
CoX-II-Inh.
Ausgewählte Projektbeispiele / Projekte A–D
Markteintritt, Technologie und Produktstrategie
Die Projekte A–D zeigen europäische Marktbewertungen, Technologieassessment und produktbezogene Strategiearbeit in Biotechnologie und Pharma.
Selected Client Projects - 1Grafik in englischer Sprache. Zum Lesen vergrößern; mit dem Zurück-Knopf zur Seite zurückkehren.
Ausgewählte frühere Mandate, anonymisiert. Dargestellt sind Ausgangslagen, Projektziele, vereinbarte Leistungsbeiträge und der jeweilige Umfang – keine zusätzlichen oder garantierten Geschäftsergebnisse.
Originalangaben zu den Projekten lesen
Client A / Biotech
Project setting
European Market Assessment with the scope:
Expanding the own Business into EU
Special Focus on HIV and specific Oncology Indications (own assets in R&D)
Project objectives
Determination of Market Potential in the targeted Key Indications
Evaluation of conditions re. Building of an own Representation vs. Alliances
Key deliverables
Definition of Key Assumptions for Business Expansion from the US into the EU Markets
Specific Benchmarks /Country
Strategic Plan: Options for Expansion
Level / countries
G5: France, Germany, Italy, Spain, UK
Level: Corporate for Europe
Client B / Biotech
Project setting
European Market Assessment with the scope:
Expanding the own Business into EU
Special Focus on HIV and Hepatitis B (own assets in R&D)
Project objectives
Determination of Market Potential in the targeted Key Indications
Evaluation of conditions re. Building of an own Representation vs. Alliances
Key deliverables
Definition of Key Assumptions for Business Expansion from the US into the EU Markets
Specific Benchmarks /Country
Strategic Plan: Options for Expansion
Level / countries
G5: France, Germany, Italy, Spain, UK
Level: Corporate for Europe
Client C / Pharmaceutical
Project setting
Existing Franchise Analgesics, however lack of Innovation and aging Portfolio
Need to provide new Assets (e.g. Galenic Line Extentions, Device driven Applicators, NME’s) to M&S
Technology Assessment in Analgesia / Anti-Inflammatory
Identify Companies with strategic Fit for Acquisitions
Key deliverables
Technology Map
Prioritization of Technologies and / or individual Projects / Products
Prioritization of potential Acquisition / Partnering / LicensingCompanies
Level / countries
G 10
Level: Corporate for Global
Client D / Pharmaceutical
Project setting
New, innovative oral antidiabetic Drug in R&D (Phase IIIa)
No previous own Segment Expertise
Detailed Market Assessment
Technology Assessment including direct competition (current and future)
CPA - Customer Perception Audit
Project objectives
Facilitate Project Team (M&S) to gain in depth Under-standing re. Market and Competitive Environment
Assessment of the Potential of the own Project
Analysis of Price-Benchmarks
Key deliverables
Valid Project Strategy
Value Map and Key Benchmarks for Positioning and Differentiations
Business Plan including different Scenarios re. Marketing, Forecasts / Profit
Level / countries
Germany
Level: Affiliate for Germany
Ausgewählte Projektbeispiele / Projekte E–H
Entwicklung, internationale Planung und Portfolio
Die Projekte E–H verbinden Entwicklungsprojektmanagement mit internationalen Strategie-, Planungs- und Portfolioaufgaben.
Selected Client Projects - 2Grafik in englischer Sprache. Zum Lesen vergrößern; mit dem Zurück-Knopf zur Seite zurückkehren.
Ausgewählte frühere Mandate, anonymisiert. Dargestellt sind Ausgangslagen, Projektziele, vereinbarte Leistungsbeiträge und der jeweilige Umfang – keine zusätzlichen oder garantierten Geschäftsergebnisse.
Originalangaben zu den Projekten lesen
Client E / Pharmaceutical
Project setting
Inlicensed oral antidiabetic Drug in R&D (phase I /IIa)
No previous own Development finalized in this Segment
Significant Shortage of own Human Resource to manage the Project
Project objectives
Project Management
Support of specific Functional Areas
Facilitation of Exchange and Interaction with Licensing Partners
Key deliverables
Optimization of Development Process
Continuous In-Process Controlling, Benchmarking and rigorous Go / No-Go Assessments
Level / countries
International Drug Development and Approvals
Market Focus: USA
Level: Corporate for Global
Client F / Pharmaceutical
Project setting
14 Global Development Projects (phase I - IIIb)
International Development Teams
Optimizing interaction between R, D, M&S, HE&P, F&C, Patent Lawyers and Reg.A.
Optimization of Interaction with Partners
Project objectives
Implementation of LifeCycle Management Process
Validation of Global Development Plans
Validation of Global Commercial Plans
Validation of LifeCycle Plans
Key deliverables
Optimization of Benchmark Settings, Processing and Decision Making
Change Management (Resource Allocation)
Prioritization / Cancellation of Development Projects
Level / countries
Development G10
USA
Belgium
Level: Corporate for Global
Client G / Pharmaceutical
Project setting
Strategic Planning Process in Key-Markets
Need to implement Planning Guidelines to harmonize national Planning Approaches
Global summary of national Plans coordinating corporate Functions
Project objectives
Provision of Affiliate Planning Manuals and Planning Tools
Facilitation of Planning Process in the Affiliates
Challenge and Validation of Affiliate Planning
Consolidation of “Global” Plan
Key deliverables
Global Strategic Plans
Comparative Analysis and Decision of clear Action Plans
Trade-Offs re. Investments vs. Market Shares / Revenues vs. Break Evens and local / international Profitability
Level / countries
10 Key Markets: Australia, Brazil, France, Germany, Italy, Spain, Sweden, UK, USA, Japan
Level: Corporate for Global
Client H / Pharmaceutical
Project setting
Business Unit Structure with Diversified Global Portfolio
Need to implement Process identifying Projects/Products with relevance as Global Strategic, Local Strategic and Local Non-Strategic
Need for Resource Allocation Optimizat.
Project objectives
Implement Global Planning Process, following a Dual Approach (Top-Down Corporate / Bottom-Up Affiliate)
Facilitate Process / Challenge and Validation of all Planning
Key deliverables
Global Strategic Plans
Portfolio-Optimization and focus of Resources on Key-Assets
Action Plans, corresponding with Strategic Plans
Trade-Offs re. Investments vs. international Profitability
Level / countries
9 Key Markets: Brazil, Canada, France, Germany, Italy, Spain, UK, USA, Japan
Level: Corporate for Global
Ausgewählte Projektbeispiele / Projekte I–J
Unternehmensbewertung und operative Führung
Die Projekte I–J reichen von einer Exit-Bewertung bis zur Investitionsplanung und operativen Führungsverantwortung in der Medizintechnik.
Selected Client Projects - 3Grafik in englischer Sprache. Zum Lesen vergrößern; mit dem Zurück-Knopf zur Seite zurückkehren.
Ausgewählte frühere Mandate, anonymisiert. Dargestellt sind Ausgangslagen, Projektziele, vereinbarte Leistungsbeiträge und der jeweilige Umfang – keine zusätzlichen oder garantierten Geschäftsergebnisse.
Originalangaben zu den Projekten lesen
Client I / Laboratory & Candidate Screening & Production
Project setting
Evaluate and prioritize the current Technology
Evaluate and prioritize the Innovation Power of R&D-Portfolio
Evaluate the Team Capabilities
Project objectives
Provide Lead Investors with an Exit Rationale (Assess an Exit Potential for a Take Over by an International Group)
Define Upsides and Downsides
conduct a valid SWOT Analysis
Key deliverables
Clear Go-Assessment for an Exit, targeted to the Key Investors
Demonstration of “Taking Care” re. Due Diligence and Guarantee Issues
Convincing the Client Team
Level / countries
International Drug Development and Approvals
Market Focus: Germany, EU, wuith focus on the USA
Client J / Medical Technology (E-Health / Telemedicine
Project setting
Evaluate and prioritize the current Technology
Evaluate and prioritize the Innovation Power of R&D-Portfolio and further Needs
Project objectives
Validation of Global Development Plan
Validation of Global Commercial Plan
Validation of LifeCycle Plan
Evaluate the Team Capabilities to perform adequate IT issues
Evaluate Outsourcing Opportunities
Evaluate Supply Chain Optimization
Evaluate Market Potentials, also by demontraging Medical Needs
Evaluate further Investment Ratios by previous Key Investors
Key deliverables
Implementation of LifeCycle Management Process
Production of advances Business Plan /(Development, Manufacturing, Market Supply, Portfolio Spread, Resource Allocation)
Provision of corresponding Investment Frame, in order to finance either until own commercial Break Even or until Exit.
After Consulting:
Taking Over Function as CEO and CFO (2010 to 2013)
Followed by Vice President Business Development and Strategy
Level / countries
Germany
EU
Eastern Europe
Arabs
USA
Development G10
USA
Erfahrung
Evidenz ohne Logo-Sammlung
Öffentliche Cases werden anonymisiert und nach Entscheidungssituation strukturiert. Client Namen, Marken, Logos, Kennzahlen und Zitate erscheinen nur nach dokumentierter Freigabe. Für geeignete Mandate können vertrauliche Referenzgespräche vereinbart werden.
Vorgesehene Case Typen. Launch Readiness, Portfolio Priorisierung, ICCBA und Commercial Performance, Organisations und Prozessdesign, Interim Executive Mandate sowie Partnering oder Transaktion.
